logo
    Extended-release triamcinolone provides prolonged relief for patients who failed standard corticosteroid injection for knee osteoarthritis; a pragmatic retrospective study
    1
    Citation
    24
    Reference
    10
    Related Paper
    Citation Trend
    Abstract:
    Identify if extended-release triamcinolone has a longer duration of action in a cohort of patients who have had limited duration of relief from prior corticosteroid injection.
    Keywords:
    Outpatient clinic
    Purpose Trigger finger is a commonly occurring hand condition that presents with symptoms of pain, clicking, locking, and catching of the finger. A common non-operative management option is corticosteroid injection. The purpose of this study was to evaluate the short-term patient response to corticosteroid injections for trigger finger. Methods The patients of six fellowship-trained orthopedic hand surgeons who underwent a corticosteroid injection for trigger finger between June 2019 and October 2019 were invited to participate in this study. Patients were contacted by phone at one week, two weeks, and three weeks after the injection to complete a questionnaire regarding their pain and triggering symptoms. Medical records were also reviewed to collect basic demographic data. Results A total of 452 patients were included in the study. At the final follow-up, 82.4% of patients reported complete pain relief, 16.3% had partial relief, and 1.2% had no relief from their pain. For their triggering symptoms, 65.9% reported complete triggering relief, 30.4% had partial relief, and 3.5% had no triggering relief. It took an average of 6.6 days following injection for patients to experience complete pain relief, and an average of 8.1 days for patients to experience complete triggering relief. Conclusions This analysis found that most patients experience relief of pain and triggering at three weeks following corticosteroid injection. The majority of patients experienced some pain relief within the first week following corticosteroid injection, while improvement in triggering appeared to lag behind pain relief.
    Trigger finger
    Symptom relief
    Citations (3)
    It is the purpose of this paper to describe the results of therapy as observed in patients with erosive lichen planus of the oral mucous membranes through the use of a topically applied corticosteroid, triamcinolone acetonide, incorporated in a new adhesive vehicle,1the latter having been specifically designed for the more efficient application of therapeutic agents to oral mucous membranes. Triamcinolone acetonide2,3(Kenalog), a synthetic corticosteroid derived from triamcinolone, has been observed to be a particularly active and useful topical agent, although it is also an active corticosteroid when administered systemically.4

    Methods

    Twenty patients, including 7 men and 13 women, aged 33 to 56, treated for erosive lichen planus of the oral mucosa, are the subjects of this report. All patients had been treated previously with one or more therapeutic agents, including, but not restricted to vitamins, sex hormones, placebos, other corticosteroids, and mouth washes, but without
    Mucous membrane
    Refractory (planetary science)
    Acetonide
    Twenty-six patients with frozen shoulder syndrome (Stage 2 and 3) were included in this study conducted at Dr. Kariadi General Hospital, Semarang, Indonesia and randomly allocated into 2 groups: 40 mg triamcinolone intra-articular injection and triamcinolone oral tablets. The result showed that triamcinolone intra-articular injection group "cured" rate was 5.8 times higher at week one compared to the triamcinolone tablet group. Sixty-two percent of the cases with triamcinolone intra-articular injection achieved their "cured" condition after one week of therapy, compared with only 14% of the triamcinolone tablets group. We conclude that, intra-articular corticosteroid injection provide faster improvement compared to oral route.
    Citations (45)